Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics disclosed yesterday that it aims to raise roughly $4.3 million through the public offering of 630,000 shares of its common stock at a price of $6.81 per share.

Proceeds of the offering will be used for working capital, repayment of indebtedness, and general corporate purposes, the company said in a filing with the US Securities and Exchange Commission. Interpace said it will have approximately 2.8 million shares outstanding after the close of the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Mar
28
Sponsored by
Qiagen

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.